AC Immune SA (ACIU)
Automate Your Wheel Strategy on ACIU
With Tiblio's Option Bot, you can configure your own wheel strategy including ACIU - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ACIU
- Rev/Share 0.2818
- Book/Share 0.9441
- PB 1.5024
- Debt/Equity 0.0546
- CurrentRatio 1.5329
- ROIC -0.4579
- MktCap 140345276.2193
- FreeCF/Share 0.4513
- PFCF 3.0972
- PE -2.7346
- Debt/Assets 0.0245
- DivYield 0
- ROE -0.4522
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
AC Immune (ACIU) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.21 per share a year ago.
Read More
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseases Positive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkinson's disease (PD) Additional ACI-7104.056 Phase 2 interim results (pharmacodynamics and biomarkers) expected in Q2 2025 Presentations at International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) highlight leadership in active immunotherapy and promising data on early-stage assets Cash resources of CHF 145.7 million as of March 31, 2025 provide funding into Q1 …
Read More
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company's industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases Multiple presentations at the International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) showcasing the diversity of the company's precision medicine pipeline Lausanne, Switzerland, March 25, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) taking place in Vienna, …
Read More
AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
About AC Immune SA (ACIU)
- IPO Date 2016-09-23
- Website https://www.acimmune.com
- Industry Biotechnology
- CEO Dr. Andrea Pfeifer Ph.D.
- Employees 133